<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336424">
  <stage>Registered</stage>
  <submitdate>17/01/2011</submitdate>
  <approvaldate>19/01/2011</approvaldate>
  <actrnumber>ACTRN12611000071921</actrnumber>
  <trial_identification>
    <studytitle>A randomised placebo controlled crossover trial to evaluate the effects of different doses of taurocholic acid in an enema formulation on gastrointestinal hormone secretion and appetite in healthy humans for the future design of treatments for Type 2 diabetes mellitus and obesity</studytitle>
    <scientifictitle>A randomised placebo controlled crossover trial to evaluate the effects of different doses of taurocholic acid in an enema formulation on gastrointestinal hormone secretion and appetite in healthy humans for the future design of treatments for Type 2 diabetes mellitus and obesity</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Designing future treatments for type 2 diabetes mellitus</healthcondition>
    <healthcondition>Designing future treatments for obesity</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Normal oral and gastrointestinal development and function</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Each healthy volunteers will undergo three treatments (2 with different doses of taurocholic acid 1500mg and 3500mg and one  with control), in double-blind, randomised fashion, separated by 3 - 7 days. On each day the test material will be administered as an enema, and each session will last 210 min.</interventions>
    <comparator>Enema containing vehicle only</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Plasma concentrations of glucagon-like peptide- 1 (GLP-1), Peptide YY (PYY), and oxyntomodulin</outcome>
      <timepoint>T= -5, 10, 30, 60, 90, 120, 180 min, where the enema is administered at T=0 min</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Appetite scores by visual analogue questionnaire</outcome>
      <timepoint>T= -5, 10, 30, 60, 90, 120, 180 min, where the enema is administered at T=0 min</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Food intake from an ad libitum buffet meal</outcome>
      <timepoint>Offered over 30 minutes, from 180 - 210 min after the enema is administered</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy subjects; Body mass index (BMI) 19 - 30 kg/m2; Haemoglobin &gt; 135 g/L</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Medications affecting gut function; Alcohol intake &gt;20g daily or cigarette smoking; Significant gastrointestinal disease or surgery; Impaired liver or renal function; Blood donation within 3 months</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>numbered containers</concealment>
    <sequence>computer-generated random number table</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>31/01/2011</anticipatedstartdate>
    <actualstartdate>2/03/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate>3/05/2011</actualenddate>
    <samplesize>12</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal Adelaide Hospital</primarysponsorname>
    <primarysponsoraddress>North Terrace Adelaide South Australia 5000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council</fundingname>
      <fundingaddress>National Health and Medical Research Council 
GPO Box 1421 Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Satiogen Pharmaceuticals Inc.</fundingname>
      <fundingaddress>Satiogen Pharmaceuticals Inc. 350 Tenth Ave, 
Suite 820 San Diego, CA 92101</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study aims to establish whether taurocholic acid, administered as an enema, can stimulate secretion of the gut peptides GLP-1, PYY, and oxyntomodulin, and suppress subsequent appetite and food intake. This information could be useful in designing treatments for type 2 diabetes and obesity.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital Human Research Ethics  Committee</ethicname>
      <ethicaddress>Level 3, Hanson Institute Royal Adelaide 
Hospital, North Terrace, Adelaide SA 5000</ethicaddress>
      <ethicapprovaldate>24/12/2010</ethicapprovaldate>
      <hrec>101205</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>A/Prof Chris Rayner</name>
      <address>Discipline of Medicine 
Royal Adelaide Hospital 
North Terrace 
Adelaide SA 5000</address>
      <phone>+61 8 82222916</phone>
      <fax>+61 8 82233870</fax>
      <email>chris.rayner@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>A/Prof Chris Rayner</name>
      <address>Discipline of Medicine 
Royal Adelaide Hospital 
North Terrace 
Adelaide SA 5000</address>
      <phone>+61 8 82222916</phone>
      <fax>+61 8 82233870</fax>
      <email>chris.rayner@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>A/Prof Chris Rayner</name>
      <address>Discipline of Medicine 
Royal Adelaide Hospital 
North Terrace 
Adelaide SA 5000</address>
      <phone>+61 8 82222916</phone>
      <fax>+61 8 82233870</fax>
      <email>chris.rayner@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Chris Rayner</name>
      <address>Discipline of Medicine Royal Adelaide Hospital North Terrace Adelaide SA 5000</address>
      <phone>+61 8 82222916</phone>
      <fax>+61 8 82233870</fax>
      <email>chris.rayner@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>